Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
28/10/2026 14:51
BRIEF-Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA Oct 28 (Reuters) - Shanghai Junshi Biosciences 688180.SS:
RECEIVES SUPPLEMENTAL DRUG APPROVAL FROM NMPA
APPROVAL GRANTED FOR TORIPALIMAB AS MONOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab